An Update on Inhibitors of Human 14 kDa Type II s-PLA2 in Development

Dane M. Springer

Abstract

Recent progress in the development of inhibitors of human Type II s-PLA2 as potential anti-inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY-315920 (S-5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY-315920 is extensively reviewed, as well as the current status of other small molecular weight inhibitors of Type II s- PLA2 that have been reported to be in late-stage development.

« Previous Next »

Rights & Permissions Print Cite

Current Pharmaceutical Design

Title: An Update on Inhibitors of Human 14 kDa Type II s-PLA2 in Development

Volume: 7 Issue: 3

Author(s): Dane M. Springer

Affiliation:

Abstract: Recent progress in the development of inhibitors of human Type II s-PLA2 as potential anti-inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY-315920 (S-5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY-315920 is extensively reviewed, as well as the current status of other small molecular weight inhibitors of Type II s- PLA2 that have been reported to be in late-stage development.

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Dane M. Springer , An Update on Inhibitors of Human 14 kDa Type II s-PLA2 in Development, Current Pharmaceutical Design 2001; 7 (3) . https://dx.doi.org/10.2174/1381612013398275

DOI https://dx.doi.org/10.2174/1381612013398275	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

About this journal

Call for Papers in Thematic Issues

Submission closes on : 30 July, 2024

"Tuberculosis Prevention, Diagnosis and Drug Discovery"

The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more

Guest Editor(s): Dr. M Pinheiro

Submission closes on : 18 September, 2024

Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions

Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more

Guest Editor(s): Dr. Sidharth Mehan

Submission closes on : 29 September, 2024

Emerging and re-emerging diseases

Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more

Guest Editor(s): Marcos Roberto Tovani Palone

Submission closes on : 30 June, 2024

Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances

In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more

Guest Editor(s): Dr. MF Chedid